TransMedics, Inc.

TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers

TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers

March 4, 2010

ANDOVER, Mass., March 4 /PRNewswire/ -- TransMedics, Inc., a leading medical device company focusing on delivering the next standard of care for solid organ transplantation worldwide, announced today the closing of a $36 million financing round. The financing was lead by Foundation Capital and Kleiner Perkins Caufield & Byers (KPCB) and also included investments by Flagship Ventures and by several existing investors.

Acceleron Pharma, Inc.

Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States

Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States

March 10, 2010

CAMBRIDGE, Mass. – March 10, 2010 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat and the vasculature, today announced that it was recognized by VentureSource, a unit of Wall Street Journal owner News Corp. as one of the top 50 venture capital-backed companies in the United States.

VisEn Medical, Inc.

VisEn Launches New VivoTag® 680 XL Fluorescence Molecular Imaging Label

VisEn Launches New VivoTag® 680 XL Fluorescence Molecular Imaging Label

March 11, 2010

Extends VisEn’s Leading Fluorescence Molecular Imaging Labeling Portfolio to Enable Enhanced Imaging Applications of Biomarkers in Research and Drug Development

BEDFORD, MA (March 11, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

Ze-gen, Inc.

Ze-gen Named Top 50 Greentech Startup

Ze-gen Named Top 50 Greentech Startup

March 11, 2010

Boston, MA — March 11, 2010 — Ze-gen, Inc., a clean energy company developing advanced gasification technology to convert waste materials into synthesis gas, announced today that Greentech Media has chosen Ze-gen as one of the Top 50 VC-funded Cleantech Startups. The list includes companies from every sector of the cleantech industry, including green building, solar, wind, geothermal, smart grid, energy storage, next generation vehicles, and gasification.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc. Completes Initial Public Offering

AVEO Pharmaceuticals, Inc. Completes Initial Public Offering

March 18, 2010

CAMBRIDGE, Mass., Mar 18, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.

VisEn Medical, Inc.

VisEn Launches New Gastrosense™ 750 Fluorescence Imaging Agent

VisEn Launches New Gastrosense™ 750 Fluorescence Imaging Agent

April 25, 2010

Extends VisEn’s Leading Fluorescence Imaging Agent Portfolio to Enable Real Time Measurements of Gastric Motility and Related Drug Effects In Vivo

BEDFORD, MA (March 25, 2010)—VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Closes $15 Million Series C Financing

Selecta Biosciences, Inc. Closes $15 Million Series C Financing

April 5, 2010

Company To Advance New Class of Synthetic Vaccines into Clinical Development based on targeted Synthetic Vaccine Particle (tSVP) platform

Pervasis Therapeutics, Inc.

Pervasis Announces Start of Second Clinical Program, Targeting Peripheral Arterial Disease

Pervasis Announces Start of Second Clinical Program, Targeting Peripheral Arterial Disease

April 7, 2010

CAMBRIDGE, Mass., April 7 /PRNewswire/ Pervasis Therapeutics announced today that it enrolled the first patient in a new Phase 1/2 clinical study exploring the potential of PVS-10200 to prevent restenosis in patients who undergo an angioplasty and stent procedure for the treatment of peripheral arterial disease (PAD).

LS9

LS9’s UltraClean Diesel™ Receives EPA Registration

LS9’s UltraClean Diesel™ Receives EPA Registration

April 13, 2010

Diesel Replacement Offers 85% Reduction in Carbon Footprint

(PRWEB) -- LS9, Inc (http://www.ls9.com)., the Renewable Petroleum Company™, today announced that its UltraClean Diesel™, a diesel replacement product offering an 85% reduction in carbon footprint, was officially registered by the United States Environment Protection Agency (EPA). As a registered fuel, LS9’s UltraClean Diesel™ can be sold commercially in the United States.

Joule Unlimited, Inc.

Joule Closes $30M Funding Round

Joule Closes $30M Funding Round

April 27, 2010

Proceeds to help accelerate the drive of renewable solar fuels from lab to commercialization

Cambridge, Mass. – April 27, 2010 – Joule today announced the closing of a $30 million second round of funding, further strengthening the company’s position as it advances from testing to high-capacity production of renewable diesel fuel starting in 2012. The round includes investments from undisclosed institutional and private sources that joined Flagship Ventures, Joule’s founding venture capital investor.